



NEWS RELEASE

Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference

2023-01-03

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 41st Annual J.P. Morgan Healthcare conference being held January 9-12 in San Francisco. Tony J. Hunt, President and Chief Executive Officer, will present on Tuesday, January 10, 2023, at 2:15 p.m. PST.

A live webcast of the presentation will be accessible through the **Investor Relations** section of the Company's website, and will be available for replay for a limited period of time following the conference event.

About Repligen Corporation

Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration, Chromatography, Process Analytics, Fluid Management and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and we also have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at <http://www.repligen.com>. Follow us on **LinkedIn** and **Twitter**.

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations
(781) 419-1881
investors@repligen.com

Source: Repligen Corporation